Teleflex Inc. (TFX) saw its shares plummet 5.01% in Friday's trading session, following the company's disappointing fourth-quarter earnings report and weak 2025 guidance. The medical device maker's revenue for Q4 2024 missed analyst expectations, and its projected 2025 revenue growth outlook of just 1-2% year-over-year, excluding foreign exchange impacts, fell short of consensus estimates.
Adding to investor concerns, Teleflex announced plans to separate its Urology, Acute Care, and OEM segments into a publicly traded company by mid-2026. While the strategic move may deliver long-term benefits, analysts raised questions about the current state of the business and the uncertainties surrounding the planned spinoff.
In response to the challenging growth outlook and separation plans, several Wall Street analysts downgraded Teleflex and lowered their price targets on the stock. Firms like RBC Capital, Raymond James, and Piper Sandler cited concerns over slowing fundamentals, particularly in the company's Urolift business, and the disruption that typically accompanies such corporate actions.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。